id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-1422	Ueda, Yuichiro; Ishii, Hiroki; Kitano, Taisuke; Shindo, Mitsutoshi; Miyazawa, Haruhisa; Ito, Kiyonori; Hirai, Keiji; Kaku, Yoshio; Mori, Honami; Hoshino, Taro; Ookawara, Susumu; Kakei, Masafumi; Tabei, Kaoru; Morishita, Yoshiyuki	Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers	2016	6	.pdf	application/pdf	3677	246	52	It is also a major risk factor for the develop- ment of cardiovascular disease.4 A poorly controlled blood glucose level and hypertension are the main contributors to progression to end-stage renal disease and the development of cardiovascular disease in DMN.5,6 Appropriate manage- ment of blood glucose and blood pressure levels is important to improve the prognosis of patients with DMN.7–9 Renin–angiotensin–aldosterone system (RAAS) block- ers are used as first-line agents for blood pressure control in DMN patients. They have been reported to decrease blood pressure and have beneficial nephroprotective and cardiopro- tective effects.10–12 For blood glucose control, although many kinds of hypoglycemic agents have been developed, most cannot be used in DMN patients with decreased renal function because they have diminished elimination by the kidneys, and may cause unfavorable side effects.	cache/dti-1422.pdf	txt/dti-1422.txt